A look at infectious agents as a possible causative factor in cardiovascular disease: Part III

Laboratory Medicine

Volumn 34, Issue 5, 2003, Pages 388-396

  Vojdani, Aristo ^a  

^a Immunosciences Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DETECTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HYPERCOAGULABILITY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION; INFECTION PREVENTION; MOLECULAR MIMICRY; NONHUMAN; REGULATORY MECHANISM; REVIEW; RISK FACTOR;

CYTOMEGALOVIRUS;

EID: 0037407562     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/DGLW-RYEA-3E9U-H3DP     Document Type: Review

References (69)

1. Van Dam-Mieras MC, Bruggeman CA, Muller AD, et al. Induction of endothelial cell procoagulant activity by cytomegalovirus infection. Thrombosis Res. 1981;41:61-75.
2. Melnick JL, Petrie BL, Dreesman GR, et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet. 1983;2:644-647.
3. Adam E, Probstfield JL, Burek J, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 1987;2:291-293.
4. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566.
5. Nieto FJ, Sorlie P, Comstock GW, et al. Cytomgegalovirus infection, lipoprotein(a), and hypercoagulability: An atherogenic link? Arterioscl Thromb Vasc Biol. 1991;17:1781-1785.
6. Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/herpes virus and carotid atherosclerosis: The ARIC study. J Med Virol. 1994;42:33-37.
7. Speir E, Modali R, Huang E, et al. Potential role of human cytomegalovirus and P53 interaction in coronary restenosis. Science. 1994;265:391-394.
8. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996;94:922-927.
9. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-630.
10. Chiu B, Viira E, Tucker W, et al. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.
11. Zhu J, Quyyumi AA, Norman JE, et al. Cytomegaloviruses in the pathogenesis of atherosclerosis: The role of inflammation, as reflected by elevated C-reactive protein levels. JACC. 1999;34:1738-1743.
12. Melnick JL. Cytomegalovirus DNA in the arterial walls. J Med Virol. 1984;42:170-174.
13. Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct causation of the vascular wall. Circulation. 1999;100:1569-1575.
14. Zhou YF, Shou M, Harrell RF, et al. Chronic nonvascular cytomegalovirus infection: effects on the neointimal response to experimental vascular injury. Cardiovascular Research. 2000;45:1019-1025.
15. Zhu J, Shearer GTM, Norman JE, et al. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: Gender-based differences in inflammation and type of immune response. Circulation. 2000;102:2491-2496.
16. Butch GE, Sun S, Colcolough H, et al. Coxsackie B viral myocarditis and valvulitis identified in routine autopsy specimens by immunofluorescent techniques. Am Heart J. 1967;74:13-23, 1967.
17. Bell EJ, Grist NR. Coxsackie virus infections in patients with acute cardiac disease and chest pain. Scott Med J. 1968;13:47-51.
18. Beisel K, Wolfgram L, Herskowitz A, et al. Differences in severity of coxsackievirus B3-induced myocarditis among H-2 congenic mouse strains. Prog Leuko Biol. 1985;3:195-201.
19. Baboonian C, Davies MJ, Booth JC, et al. Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol. 1997;223:31-52.
20. Gaunt CJ. Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin Immunol Immunopathol. 1993;68:129-134.
21. Henke A, Huber S, Stelzner A, et al. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol. 1995;69:6720-6728.
22. Wolfgram L, Rose NR. Coxsackievirus infection as a trigger of cardiac autoimmunity. Immuno Res. 1989;8:61-80.
23. Cambridge G, MacArthur CGC, Waterson AP, et al. Antibodies to Coxsackie B viruses in congestive cardiomyopathy. Br Heart J. 1979;41:692-696.
24. Engle MA, McCabe JC, Ebert PA, et al. The postpericardiotomy syndrome and anti-heart antibodies. Circulation. 1974;49:401-406.
25. Nikoskelainen Y, Kalliomaki YL, Lapinleimu K, et al. Coxsackie B virus antibodies in myocardial infarction. Acta Med Scand. 983;214:29-32.
26. Wolfgram LJ, Beisel KW, Rose NR. Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J Exp Med. 1985;161:1112-1116.
27. Alvarez FL, Neu N, Rose NR, et al. Heart-specific autoantibodies induced by coxsackievirus B3: Identification of heart autoantigens. Clin Immunol Immunopathol. 1987;43:129-139.
28. Gauntt CJ. Anfi-Coxsackievirus B3 neutralizing antibodies with pathological potential. Eur Heart J. 1991;12:124-129.
29. Hohenadl C, Klingel K, Rieger P, et al. Investigation of the coxsackievirus B3 nonstructural proteins 2B, 2C and 3AB: generation of specific polyclonal antisera and detection of replicating virus in infected tissue. J Virol Meth. 1994;47:279-295.
30. Wolfgram LJ, Rose NR. Coxsackievirus as a trigger of cardiac autoimmunity. Immunol Res. 1989;8:61-80.
31. Rose NR. Viral damage or "molecular mimicry" - placing the blame in myocarditis. Nature Medicine. 2000;6:631-632.
32. Rose NR. Myocarditis from infection to autoimmunity. The Immunologist. 1996;4:67-70.
33. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol. 1978;93:527-617.
34. Young RA, Elliot TJ. Stress proteins, infection, and immune surveillance. Cell. 1989;59:5-8.
35. Kol A, Bourcier T, Lichtman AH, et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells and macrophages. J Clin Invest. 1991;103:571-577.
36. Vayssier C, Mayrand D, Grenier D. Detection of stress proteins in Porphyromonas gingivalis and other oral bacteria by Western immunoblotting analysis. FEMS Microbiol Lett. 1994;121:303-307.
37. Murray DL, Ohlendorf DH, Schlievert PM. Staphylococcal and streptococcal superantigens: Their role in human diseases. ASM News. 1995;61:229-235.
38. Anderton SM, van der Zee R, Goodacre JA. Inflammation activates self-hsp60-specific T-cells. Eur J Immunol. 1993;23:33-38.
39. Aoyagi T, Yamazaki K, Kabasawa-Katoh Y, et al. Elevated CTLA-4 expression on CD4 T-cells from periodontitis patients stimulated with Porphyromonas gingivalis outer membrane antigen. Clin Exp Immunol. 2000;119:280-286.
40. Yamazaki K, Ohsawa Y, Tabeta K, et al. Accumulation of heat shock protein 60-reactive T-cells in the gingival tissues of periodontitis patients. Infect Immun. 2002;70:2492-2501.
41. Breloer M, Dorner B, More SH, et al. Heat shock proteins as "danger signals:" eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-ã production in T-cells. Eur J Immunol. 2001;31:2051-2059.
42. Woodland DL. Immunity and retroviral superantigens in humans. Trends Immunology. 2002;23:57-58.
43. Lamb JR, Bal V, Mendez-Samperio P, et al. Stress proteins may provide a link between the immune response to infection and autoimmunity. Int Immunol. 1989;1:191-196.
44. Nilsson E, Klareskog L. Role of hsp60 during autoimmune and bacterial inflammation. Immunol Rev. 1991;121:91-112.
45. Macht LM, Elson CJ, Kirwan JR, et al. Relationship between disease severity and responses by blood mononuclear cells from patients with rheumatoid arthritis to human heat-shock protein 60. Immunology. 2000;99:208-214.
46. Mayr M, Metzler B, Kiechl S. et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1991;99:1561-1566.
47. Wick G. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
48. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255-259.
49. Tabeta K, Yamazaki K, Hotokezaka H, et al. Elevated humoral immune response to the heat shock protein 60 (hsp60) family in periodontitis patients. Clin Exp Immunol. 2000;120:285-293.
50. Qingbo X, Dietrich H, Steiner H, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscle Thromb. 1992;12:789-799.
51. Kleindienst R, Qingbo X, Willeit J, et al. Demonstration of heat shock protein 60 expression and T lymphocytes bearing a/β or γ/δ receptor in human atherosclerotic lesions. Am J Path. 1993;142:1927-1937.
52. Rose NR, Herskowitz A, Neumann DA, et al. Autoimmune myocarditis: A paradigm of post-infection autoimmune disease. Immunology Today. 1998;9:117-119.
53. Fairley CK, Ryan M, Wall PG, et al. The organisms reported to cause infective myocarditis and pericarditis in England and Wales. J. Infect. 1996;32:223-225.
54. Van de Rijn I, Bleiweis AS, Zabriskie JB. Antigens in Streptococcus mutans cross-reactive with human heart muscle. J Dent Res. 1976;55C:59-66.
55. Van de Rijn I, Zabriskie JB, McCarty M. Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody, and isolation and characterization of the streptococcal antigen. J Exp Med. 1977;146:579-585.
56. Ferretti JJ, Shea C, Humphrey MW. Cross-reactivity of Streptococcus mutans antigens and human heart tissue. Infect Immun. 1980;30:69-74.
57. Hughes M, MacHardy SM, Sheppard AJ, et al. Evidence for an immunological relationship between Streptococcus mutans and human cardiac tissue. Inject Immun. 1980;27:576-580.
58. Dale JB, Beachey EH. Multiple heart cross-reactive epitopes of streptococcal M proteins. J Exp Med. 1985;161:113-119.
59. Ayakawa GY, Siegel JL, Crowley PJ, et al. Immunochemistry of the Streptococcus mutans BHT cell membrane: Detection of determinants cross-reactive with human heart tissue. Infect Immun. 1985;48:280-286.
60. Doyle G, Everhart D, Mallett C, et al. Demonstration of shared antigenic determinants between Streptococcus mutans BHT cell membrane, human heart tissue and myosin using monoclonal antibodies to S. mutans. J Gen Microbiol. 1986;132:2885-2890.
61. Cunningham MW, Hall NK, Krisher KK, et al. A study of anti-group A streptococcal monoclonal antibodies cross-reactive with myosin. J Immunol. 1986;136:293-298.
62. Ayakawa GY, Bleiweis AS, Crowley PJ, et al. Heart cross-reactive antigens of mutans streptococci share epitopes with group A streptococci and myosin. J. Immunol. 1988;140:253-257.
63. Fenderson PG, Fischetti VA, Cunnigham MW. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol. 1989;142:2475.
64. Cunningham MW. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence gly-lys-ser-lys-gln in M protein. J Immunol. 1989;144:2677-2683.
65. Cunningham MW. Group A streptococci: Molecular mimicry, autoimmunity, and infection. In Microbial Adhesion and Invasion. Hood M, Switalski KS, eds. New York: Springer-Verlag. 1992.
66. Haffejee I. Rheumatic fever and rheumatic heart disease: The current status of its immunology, diagnostic criteria and prophylaxis. Q J Med. 1992;84:641-647.
67. Van de Rijn I, Bleiweis AS, Zabriskie JB. Antigens in Streptococcus mutans cross-reactive with human heart muscle. J Dent Res. 1976;55C:59-66.
68. Van de Rijn I, Zabriskie JB, McCarty M. Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody, and isolation and characterization of the streptococcal antigen. J Exp Med. 1977;146:579-585.
69. + T-cell-dependent myocarditis in MRL/++ mice and induces partial tolerance against coxsackieviral myocarditis. J Immunol. 1996;156:3528-3534.